tbuckley/cabot-search huggingface dataset:
吡格列酮对2型糖尿病患者血浆致动脉硬化指数的影响
Authors: 郝亚荣, 何小俊, 韩其蔚, 张黎军, 邬松林
Journal: BMJ (2005)

将70名2型糖尿病患者以随机双盲法分为吡格列酮组(35例)和安慰剂组(35例),治疗3个月后,检测两组服药前后空腹血糖、空腹胰岛素、糖化血红蛋白、甘油三酯和高密度脂蛋白胆固醇的水平,并计算胰岛素敏感指数和血浆致动脉硬化指数.治疗后吡格列酮组空腹血糖、空腹胰岛素、糖化血红蛋白、甘油三酯、血浆致动脉硬化指数明显下降(P＜0.01),高密度脂蛋白胆固醇、胰岛素敏感指数显著升高(P＜0.01),且血浆致动脉硬化指数与胰岛素敏感指数呈负相关(r=-0.578,P＜0.01);安慰剂组各参数于治疗前后比较差异无统计学意义(P＞0.05).说明吡格列酮能够显著降低2型糖尿病患者的血浆致动脉硬化指数。
Research progress on association between serum cystatin C and heart failure
Authors: Ping Wang, Zengfeng Su
Journal: BMJ (2017)

Serum cystatin C (Cys-C) is a cysteine protease inhibitor and has been used as an indicator of early renal function damage. The recent studies have found that Cys-C is closely related to the occurrence, development and prognosis of heart failure. This article reviews the recent research progress on the association between Cys-C and heart failure.


Key words: 
Heart failure; Cystatin C
Prognostic effect of specific <i>RAS/BRAF</i> mutations in patients (pts) with metastatic colorectal cancer (mCRC).
Authors: Ben George, Bradley W Taylor, Matthew Lasowski, Paul S. Ritch, Aditya Varnam Shreenivas, Sakti Chakrabarti, Mandana Kamgar, Michael T Zimmermann, Honey V Reddi, Raul Urrutia, James P. Thomas
Journal: Journal of Clinical Oncology (2020)

4050 Background: Somatic mutations in KRAS, HRAS, NRAS (extended RAS) and BRAF have prognostic and predictive impact in pts with mCRC. We analyzed the prognostic impact of specific somatic mutations in extended RAS and BRAF. Methods: We retrospectively reviewed the electronic medical records of pts with mCRC at our institution who underwent comprehensive genomic profiling (CGP) utilizing the Foundation One assay. DNA was extracted from clinical specimens and CGP was performed on hybrid-capture, adaptor ligation-based libraries for up to 315 genes plus 47 introns from 19 genes frequently rearranged in cancer. BRAF mutations were classified as class I, II and III according to accepted nomenclature. Fisher’s exact test and Kaplan Meier estimates were used for statistical analyses. This project was approved by the Medical College of Wisconsin Institutional Review Board. Results: 273 pts were identified - median age at diagnosis was 57, 48% were male. Somatic mutations in extended RAS were found in 138 (50%) pts, majority being mutations in KRAS (46%). Among pts with KRAS mutations, codon 12, 13, 61 and 146 mutations accounted for 73%, 11%, 4% and 6% respectively while KRAS G12C mutations accounted for 9%. BRAF mutations were detected in 22 (8%) pts - BRAF V600E and non–V600E mutations accounting for 4.4% and 3.6% respectively. Among pts with BRAF mutations, 17 (77%) were kinase domain mutations, 16 of which could be further classified as class I (12/16), II (1/16) and III (3/16). Median overall survival (mOS) for the entire cohort was 26.4 months (mo). KRAS mutated pts had a mOS of 25.8 mo; pts with KRAS G12C mutation had a mOS of 23 mo compared to 27.1 mo for pts with other KRAS mutations (p &lt; 0.001).Pts with BRAF mutation had a mOS of 26.2 mo; pts with BRAF V600E mutation had a mOS of 14.1 mo compared to 30.6 mo for pts with BRAF non-V600E mutations (p = 0.1). Conclusions: The poor prognosis of pts with KRAS G12C and BRAF V600E mutations compared to pts with other KRAS and BRAF mutations merit further biologic characterization with functional assays. Individualized therapeutic strategies must be conceptualized for mCRC pts with specific RAS/BRAF mutations, considering their widely disparate prognosis and putative downstream signaling mechanisms. Dynamic molecular simulation to understand conformational changes in proteins associated with specific mutations will be pivotal to optimizing precision therapeutic strategies.
Nonconscious nonverbal synchrony and patient and physician affect and rapport in cancer treatment discussions with black and white patients.
Authors: Lauren M. Hamel, Robert Moulder, Louis Penner, Terrance Lynn Albrecht, Steven Boker, David W. Dougherty, Susan Eggly
Journal: Journal of Clinical Oncology (2020)

121 Background: Clinical communication is poorer with Black patients than with White patients, but most studies are limited to verbal communication. Nonverbal synchrony, the nonconscious coordination of movement between individuals, has been shown to reflect relationship quality. We investigated nonverbal synchrony’s association with patient and physician affect and rapport in cancer treatment discussions, and if those associations differed by patient race. Methods: We used motion detection software to measure overall synchrony and synchrony based on who is leading in the interaction (similar to leading in dancing) in video recordings of 68 Black patients and 163 White patients discussing treatment with their physicians. Naïve observers rated the interaction for six constructs: patient and physician positive and negative affect and patient-physician positive and negative rapport. We examined associations between patient race, nonverbal synchrony and the six constructs. Results: In interactions with Black patients, overall synchrony was positively associated with patients’ positive affect and positive patient-physician rapport and negatively associated with patients’ negative affect and negative patient-physician rapport. When the physician was leading, synchrony was positively associated with patients’ positive affect and positive patient-physician rapport and negatively associated with patients’ negative affect and negative patient-physician rapport. When the patient was leading, synchrony was positively associated with patients’ and physicians’ positive affect and positive patient-physician rapport, and negatively associated with patients’ negative affect and negative patient-physician rapport. In interactions with White patients, overall synchrony was positively associated with patient positive affect; when the physician was leading, synchrony was negatively associated with patient negative affect. Conclusions: This is the first study to use a dynamic, jointly-determined measure in patient-physician communication. Synchrony was related to patient and physician affect and rapport in interactions with Black patients, but only patient affect in interactions with White patients, suggesting nonverbal synchrony is particularly important in interactions with Black patients. Next, we will investigate associations with patient outcomes, such as satisfaction. Findings could contribute to physician training to enhance coordination and outcomes in oncology interactions.
Regionalization of Pancreatectomy for Pancreatic Cancer
Authors: Kjetil Søreide
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
美托洛尔联合常规抗心力衰竭药物治疗充血性心力衰竭35例
Authors: 陈智丽
Journal: BMJ (2006)

充血性心力衰竭(CHF)是引起心脏病患者住院和死亡的重要原因.近年来,心力衰竭的药物治疗有了很大的进展.β受体阻滞剂的应用进一步改善CHF患者的心功能及远期预后.我们在常规抗心力衰竭药物治疗的基础上联合应用酒石酸美托洛尔(倍他乐克)治疗心力衰竭,取得了较好的临床效果。
艾叶汁超声雾化治疗中重度褥疮29例
Authors: 盛芳, 宋修爱, 林丽华
Journal: BMJ (2006)

褥疮是指局部皮肤及皮下组织损伤,这种损伤是由压力、剪切力或身体与接触表面的摩擦力造成的[1].治疗褥疮的方法很多,但效果不一. 2000年1月至2005年1月间,我们应用艾叶汁超声雾化治疗中、重度褥疮患者29例,取得良好效果。
小剂量呋塞米致严重低血钾一例
Authors: 习森, 白宏涛
Journal: BMJ (2011)

患者男,76岁,因咳嗽、咳痰10余年,加重并喘息、夜间不能平卧3 d入院.10年前冬季患者因受凉后咳嗽、咳痰,初咳白痰,1 d后咳黄痰,日轻夜重,自服感冒药、消炎药(具体不详)后好转,以后每年冬春季均有类似发作。
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
Authors: Sumanta K. Pal, Bernard Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott, Brian I. Rini
Journal: Journal of Clinical Oncology (2020)

5062 Background: Tivozanib (T) is a potent and highly selective VEGFR inhibitor. TIVO-3 is a phase 3 study designed to compare the efficacy and safety of T with those of sorafenib (S) as 3rd and 4th line therapy in patients with metastatic RCC. Methods: Subjects with RCC who failed 2 or 3 prior systemic regimens, one of which included a VEGFR TKI other than S or T, were stratified by IMDC risk category and type of prior therapy (two TKIs; TKI plus checkpoint inhibitor (CPI); TKI plus other) then randomized in a 1:1 ratio to T or S. Results: The 2 arms were well balanced for demographics and prior cancer history. 60% of subjects had 2 prior lines of therapy and 40% had 3 prior lines. 26% had prior treatment with a CPI. Patients treated with T demonstrated PFS superiority compared to S, 5.6 (95% CI 7.3 - 5.3) v. 3.9 mos (95% CI 5.6 – 3.7; HR 0.73; p=0.02). ORR was 18% for T compared to 8% for S (p=0.02). 44% of T treated subjects experienced a grade 3 treatment-related adverse event compared to 55% for S. The predefined, interim analysis for OS performed two years after enrollment was closed had a HR of 0.99 based on 227 events. The final analysis will be presented based on an estimate of 263 events. Conclusions: T is superior to S as measured by PFS; 2-year PFS, and ORR in this heavily-treated/relapsed or refractory RCC population and is better tolerated than S. Final OS data will be updated prior to presentation. Clinical trial information: 02627963 .
A nomogram for predicting overall survival in resected non-small cell lung cancer with chemotherapy.
Authors: Yuan Zeng, Wenhua Liang, Jianxing He
Journal: Journal of Clinical Oncology (2020)

e21064 Background: Chemotherapy is very common for resected Non-Small-Cell Lung Cancer (NSCLC) patients. However, models for predicting the survival outcomes of resected NSCLC patients with chemotherapy are scarce. The aim of this study was to develop a clinical nomogram for predicting overall survival in these patients. Methods: A total of 16661 resected NSCLC with chemotherapy were cases extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified and integrated the prognostic factors to build a nomogram.The model was subjected to bootstrap internal validation with the SEER database and external validations with 1108 patients from China. The predictive accuracy and discriminative ability were illustrated by calibration, concordance index (C-index) and risk group stratification. Results: On multivariate analysis independent factors for OS were age, sex, examined lymph node count, extent of surgery, N stage, T stage and grade which were then integrated into the nomogram. The calibration curves for probability of 1-, 3-, and 5-year OS showed excellent agreement between nomogram prediction and actual observation. The C-index of the nomogram was higher than that of AJCC 8 th edition system for predicting OS (training cohort, 0.61 vs. 0.58; P &lt; 0.01; validation cohort, 0.66 vs. 0.63, P = 0.56). The stratification into different risk groups allowed significant distinction between survival curves. Conclusions: We established a nomogram that can provide individual prediction of OS for resected NSCLC patients with chemotherapy. This practical prognostic model may help clinicians for treatment planning and to guide future studies.
Very long term follow-up of high dose chemotherapy followed by autologous stem cell transplantation in high risk locally advanced triple negative breast cancer.
Authors: Bayan A Al-Share, Hadeel Assad, Judith Abrams, Abhinav Deol, Asif Alavi, Voravit Ratanatharathorn, Joseph P. Uberti, Lois Jeanne Ayash
Journal: Journal of Clinical Oncology (2020)

e13094 Background: The role of High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) in treatment of high risk locally advanced breast cancer remains unclear. This modality stopped being used for breast cancer treatment when trials in early 2000s reported Disease Free Survival (DFS) benefit but no Overall survival (OS) benefit. However, subgroup analyses of these studies reported OS benefit in young and Triple Negative Breast Cancer (TNBC). We report very long-term outcomes of high risk locally advanced TNBC treated with HDC-ASCT at our institution between 1995 and 2001. Methods: We reviewed our BMT database for women with stage IIB or III TNBC treated with HDC-ASCT. We excluded women with hormone positive, Her2/Neu positive/Unknown and metastatic disease prior to transplant per updated AJCC 7 th edition. The majority of patients underwent surgery followed by adjuvant Anthracycline and Taxane based induction chemotherapy followed by HDC-ASCT for consolidation. The HDC regimen consisted of Carmustine 600 mg/m 2 , Cyclophosphamide 5.6gm/ m 2 and Cisplatin 165mg/ m 2 (STAMP 1 regimen). Four patients received induction regimen as neoadjuvant and HDC-ASCT as adjuvant treatment per the same protocol. All patients received loco-regional radiation after ASCT. Results: 29 patients had locally advanced TNBC treated with HDC-ASCT. Median age at diagnosis was 43 years (IQR 40-51). 28 had at least 4 positive lymph nodes. Median time from diagnosis to ASCT was 5 months. Median overall survival was 17 years (95% CI, 3-19 years), and median DFS was 14 years (95% CI, 1-19). There was no treatment related mortality (TRM) at 30- and 100-days post ASCT. 12 patients (41%) were alive at median of 16 years (95% CI, 12-19) post ASCT. Conclusions: This single institution study of locally advanced high risk TNBC patients who received HDC-ASCT as part of treatment demonstrates a high long term OS exceeded historical controls. This supports a potential role for HDC-ASCT in this cohort of high risk TNBC. Considering the low TRM associated with this approach, prospective evaluation of this strategy is warranted.
A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms.
Authors: Brett James Theeler, Jinkyu Jung, Eric Burton, Javier Gonzalez, Heather Leeper, Jing Wu, Edjah Nduom, Kareem Zaghloul, Abhik Ray-Chaudhury, Martha Quezado, Mark Raffeld, Joshua E. Allen, Varun Vijay Prabhu, Martin Stogniew, Wolfgang Oster, Ying Yuan, Kenneth D. Aldape, Marta Penas-Prado, Terri Armstrong, Mark R. Gilbert
Journal: Journal of Clinical Oncology (2020)

TPS2576 Background: Blockade of the dopamine receptor D2 (DRD2) has emerged as a therapeutic target in neuro-oncology. ONC201, a first-generation imipridone that antagonizes DRD2, has demonstrated clinical activity in Diffuse Midline Gliomas, H3K27M-mutant (DMGs). Treatment options beyond surgical resection and radiation therapy are limited for most recurrent and rare primary CNS neoplasms. DRD2 blockade holds promise as a therapeutic target in multiple primary CNS cancers. ONC206 is a next generation imipridone and a chemical analog of ONC201 that possesses favorable drug properties such as oral bioavailability, robust stability, and blood-brain barrier penetrance. ONC206 exhibits enhanced allosteric inhibition of DRD2 and nanomolar affinity/potency as a DRD2 antagonist with complete antagonism and specificity for DRD2. ONC206 demonstrated broad spectrum anti-cancer efficacy in vitro across most solid tumor types tested in a panel of &gt; 1000 human cancer cell lines with nervous system tumors emerging as most responsive. In addition to its broad-spectrum activity in vitro, ONC206 efficacy has been demonstrated in xenograft mouse models. Methods: This is an open label, dose escalation, and food effect Phase I study of ONC206at the National Cancer Institute, Neuro-Oncology Branch. Adult patients 18 years and older with recurrent, primary CNS neoplasms will initially be accrued to the dose escalation portion of the study and evaluated for toxicity. Eligible diseases include recurrent glioblastoma, WHO Grade 2 and 3 infiltrating glial neoplasms, and rare primary CNS neoplasms in the NCI-CONNECT program: DMGs, ependymomas, medulloblastomas, and other rare CNS tumor types. The primary endpoint is to determine DLT during the first cycle (28 days). Dose escalation will proceed according to a standard 3+3 design. Both once weekly and more frequent dosing of ONC206 will be explored in the dose escalation scheme. After the MTD is established, food effect will be determined in a dedicated cohort using a balanced, single-dose, two-arm, two-period crossover design. Secondary endpoints will include objective response rate by RANO criteria, overall and progression-free survival, and disease control rate. Exploratory analysis of DRD2 and DRD5 expression, DRD2 dimerization, expression of MYC and N-MYC in tumor tissue in relation to clinical outcomes will also be performed.
SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.
Authors: Heather Christine Beckwith, Diana Cristina Medgyesy, Jame Abraham, Rita Nanda, Katherine H. R. Tkaczuk, Ian E. Krop, Lajos Pusztai, Shanu Modi, Monica M. Mita, Jennifer M. Specht, Sara A. Hurvitz, Hyo S. Han, Kevin Kalinsky, Sharon Wilks, Joyce O'Shaughnessy, Lowell L. Hart, Hope S. Rugo, Zahi Ibrahim Mitri, Phillip M. Garfin, Howard A. Burris III
Journal: Journal of Clinical Oncology (2020)

TPS1104 Background: LIV-1 is a highly prevalent transmembrane protein in breast cancer cells. Ladiratuzumab vedotin (LV), SGN-LIV1A, is an investigational antibody-drug conjugate (ADC) that targets LIV-1 via a humanized IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) by a protease-cleavable linker. LV is internalized when it binds LIV-1 on cell surfaces and MMAE is released, which binds tubulin and induces apoptosis. LV has been shown to be active and tolerable in metastatic breast cancer (mBC) at a recommended dose of 2.5 mg/kg every 21 days (Modi 2017). More frequent, fractionated dosing has improved the activity and/or safety of other ADCs. Thus, this study is actively accruing subjects with metastatic triple negative breast cancer (mTNBC; estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) receptor-negative) and endocrine-resistant ER+ or PR+ (hormone receptor [HR+])/HER2-negative mBC to test weekly dosing of LV (Days 1, 8, and 15 of every 3-week cycle). Methods: This study is enrolling up to 82 subjects (42 HR+/HER2-negative and 40 mTNBC) into dose escalation and dose expansion cohorts (NCT01969643). Eligible subjects are females ≥18 years old with pathologically and radiologically confirmed metastatic HR+/HER2-negative or mTNBC with at least 1 measurable lesion per RECIST v1.1. Subjects with HR+/HER2-negative disease must have received no more than 1 prior line of cytotoxic chemotherapy in the locally advanced (LA)/mBC setting, either as single agent or combination therapy. Subjects with mTNBC must have received 1 prior line of cytotoxic chemotherapy in the LA/mBC setting. Progression within 6 months of completion of neoadjuvant or adjuvant therapy is considered an LA/mBC regimen. Subjects must have adequate organ function, ECOG status of ≤1, and no ≥ Grade 2 peripheral neuropathy. Subjects with brain lesions must have received definitive treatment of the lesions. Prior therapy with MMAE-containing agents is not allowed. Dose escalation follows the modified toxicity probability interval method (Ji 2010). Dose expansion cohorts will provide data about activity and tolerability. Tumor assessments will be conducted every 2 cycles per RECIST v1.1 and all subjects will be followed for safety. Pharmacokinetics and markers of pharmacodynamics will be assessed. Primary safety endpoint is the incidence of adverse events and dose-limiting toxicities. Key efficacy endpoints include confirmed overall response rate, duration of response, and progression-free survival. Clinical trial information: NCT01969643 .
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
Authors: Anna van der Voort, Mette S. van Ramshorst, Erik D. van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Annelie J. Vulink, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnes J. van de Wouw, Caroline M. Mandigers, Laurence J. C. van Warmerdam, Jelle Wesseling, Marie-Jeanne T.F.D Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke
Journal: Journal of Clinical Oncology (2020)

501 Background: The multicenter phase III TRAIN-2 study showed high pathological complete response (pCR) rates after neoadjuvant chemotherapy with and without anthracylines plus dual HER2-blockade in stage II-III HER2-positive breast cancer patients (67% vs 68%, p = 0.95) (NCT01996267). Here we report 3-year efficacy and safety outcomes. Methods: Patients were randomly assigned (1:1) to receive 3 cycles 5-fluoruoracil (500mg/m 2 ), epirubicin (90mg/m 2 ), and cyclophosphamide (500mg/m 2 ) followed by 6 cycles paclitaxel (80mg/m 2 day 1 and 8) and carboplatin (AUC = 6mg/ml·min) (FEC-PC) or 9 cycles paclitaxel and carboplatin (PC). Both regimens were combined with trastuzumab (T; 6mg/kg, loading dose 8mg/kg) and pertuzumab (Ptz; 420mg, loading dose 840mg). Patients completed one year of trastuzumab, radiotherapy and endocrine therapy as indicated. The primary endpoint pCR was previously reported. Secondary efficacy endpoints reported here are event-free-survival (EFS) defined as time from randomization to first event (disease progression resulting in inoperability, recurrence [contralateral DCIS excluded], secondary primary malignancies, or death) and overall survival (OS), both in the intention-to-treat population. Safety endpoints are reported for patients treated with at least one dose of study medication. Results: 438 patients were randomized (219/arm) and evaluable for long-term efficacy endpoints. After a median follow-up of 48.8 months 23 EFS events occurred in the FECT-PTC-Ptz-arm and 21 in the PTC-Ptz-arm (HR 0.90; 95% CI 0.50-1.63). Three-year EFS estimates were 92.7% (95% CI: 89.3-96.2) for FECT-PTC-Ptz and 93.6% (95% CI: 90.4-96.9) for PTC-Ptz. Three-year OS estimates were 97.7% (95% CI: 95.7-99.7) for FECT-PTC-Ptz and 98.2% (95% CI: 96.4-100) for PTC-Ptz. These results were irrespective of hormone receptor and nodal status. LVEF decline ≥10% from baseline and &lt; 50% was more common in patients who received anthracyclines than in the PTC-Ptz arm (8.6% vs. 3.2%, p = 0.021). Two patients in the FECT-PTC-Ptz arm developed acute leukemia. No other new safety concerns were seen. Conclusions: The 3-year follow-up of the TRAIN-2 study confirms the results of the primary outcome that anthracylines do not improve efficacy and are associated with clinically relevant toxicity. A neoadjuvant carboplatin-taxane based regimen with dual HER2-blockade can be considered in all stage II-III breast cancer patients, regardless of hormone receptor and nodal status. Clinical trial information: NCT01996267 .
原发性高血压患者餐后血脂水平的动态分析
Authors: 吴家明, 葛亚东, 芮志莲
Journal: BMJ (2007)

测定52例原发性高血压患者和45例健康者的空腹、脂肪餐后2、4、6、8 h的血脂水平,结果显示,原发性高血压患者空腹及餐后各时间点的甘油三酯和总胆固醇曲线下面积均显著高于血压正常者(P＜0.05),餐后2、4、6、8 h的高密度脂蛋白胆固醇降低(P＜0.05),总胆固醇、低密度脂蛋白胆固醇、载脂蛋白B则显著升高(P＜0.05或P＜0.01).提示原发性高血压患者脂肪餐后甘油三酯水平异常升高,伴高密度脂蛋白胆固醇的降低是其血脂代谢异常的重要内容之一。
现代降压治疗中利尿剂的重要性和正确使用
Authors: 何秉贤, 周晓辉
Journal: BMJ (2009)

现代降压治疗,要求强化、优化、简化和达标.在临床实践中,约70%的患者平均要使用3种或更多种降压药,联合用药已成趋势.在此情况下,对各降压药应强调联合和协调,取长补短,共同制服高血压.目前在市场上,其他降压药的宣传力度大大超过利尿剂,值得注意.利尿剂是基本降压用药,最廉价、最可靠、最温和、最常联合应用,在某些情况下是其他降压药无法替代的。